Shire plc announced that the U.S. Food and Drug Administration approved Lialda delayed release tablets for the maintenance of remission in patients with ulcerative colitis.
For officials at the University of Virginia, spinning off biotechnology companies isn't an explicit goal. Rather, it's one of several techniques used to push breakthroughs from the academic world to the practical.
Initial results from a late-stage study of a potential prostate cancer treatment by Medivation Inc. will likely will be positive, according to a new report from Citi Investment Research & Analysis.
Forest Laboratories Inc. said a potential depression treatment that failed in a late-stage clinical trial announced earlier this year did well in another study of adults with major depressive disorder.
Sanofi and Regeneron Pharmaceuticals Inc. announced results from Phase 2b trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab (REGN88/SAR153191), a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor (IL-6R).
MacroGenics, Inc. announced results from Protégé, a Phase 3 clinical study of teplizumab in type 1 diabetes.
Sanofi and its subsidiary, Genzyme, announced positive results from Care-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (RRMS).
Verastem, Inc. has raised $32 million through a Series B financing, the proceeds of which will support ongoing research and development and will progress drug candidates into clinical development.
Nanobodies produced by camels have unique properties, which can be used in future drug development.
Scientists at the University of Washington have determined the atomic architecture of a sodium channel.
Novo Nordisk has been granted approval by the European Commission for FlexTouch, a prefilled insulin pen.
Approximately five to ten percent of patients with primary or metastatic cancer suffer from devastating neurological complications such as headaches, seizures, confusion, difficulty swallowing, and visual disturbances.
The Genevac Rocket Evaporator is a powerful tool proven to accelerate traditionally difficult and time consuming chiral separation and natural product sample preparation tasks.
Accelrys, Inc. announced significant enhancements to its NGS Collection for Pipeline Pilot includes dozens of new analysis pipelines for organizations seeking a single platform to support a wide variety of NGS applications.